ストックスクリーナーアプリを入手
2.78
1.77%
-0.05
アフターアワーズ：
2.81
0.03
+1.08%
前日終値:
$2.83
開ける：
$2.83
24時間の取引高:
2.57M
Relative Volume:
0.87
時価総額：
$481.04M
収益：
$7.25M
当期純損益:
$-17.41M
株価収益率:
-10.58
EPS:
-0.2627
ネットキャッシュフロー:
$-38.33M
1週間 パフォーマンス:
+3.35%
1か月 パフォーマンス:
+20.87%
6か月 パフォーマンス:
+109.02%
1年 パフォーマンス:
+869.32%
1日の値動き範囲:
$2.75
$2.95
1週間の範囲:
$2.66
$2.99
52週間の値動き範囲:
$0.2701
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
名前
Ovid Therapeutics Inc
セクター
電話
212-776-4381
住所
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.78 | 489.70M | 7.25M | -17.41M | -38.33M | -0.2627 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-11 | 開始されました | Roth Capital | Buy |
| 2025-11-17 | 開始されました | Leerink Partners | Outperform |
| 2025-10-09 | 開始されました | Oppenheimer | Outperform |
| 2025-08-08 | 再開されました | B. Riley Securities | Buy |
| 2024-06-18 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 開始されました | B. Riley Securities | Buy |
| 2024-04-29 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-05 | 開始されました | Wedbush | Outperform |
| 2023-12-21 | 開始されました | BTIG Research | Buy |
| 2023-10-13 | 開始されました | Oppenheimer | Outperform |
| 2021-04-20 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-02 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-04-20 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Ovid Therapeutics Inc (OVID) 最新ニュース
Ovid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short Interest - MarketBeat
OVID Earnings History & Surprises | EPS & Revenue Results | OVID THERAPEUTICS INC (NASDAQ:OVID) - ChartMill
Ovid Therapeutics (NASDAQ: OVID) outlines 2026 virtual meeting, pay and audit votes - Stock Titan
SEC Form DEFA14A filed by Ovid Therapeutics Inc. - Quantisnow
[ARS] Ovid Therapeutics Inc. SEC Filing - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) registers 29.9M resale shares from private placement - Stock Titan
[EFFECT] Ovid Therapeutics Inc. SEC Filing - Stock Titan
OVID Ovid Therapeutics Inc. far exceeds Q4 2025 EPS expectations, shares rise nearly four percent.Profit Guidance - Cổng thông tin điện tử Tỉnh Sơn La
OVID (Ovid Therapeutics) delivers blowout Q4 2025 results, but stock dips slightly amid mild investor profit taking.Deceleration Risk - Xã Thanh Hà
29.86M-share resale registration by Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
H.C. Wainwright reiterates Ovid Therapeutics stock rating at buy By Investing.com - Investing.com India
Ovid Therapeutics receives $53.9 million from warrant exercises By Investing.com - Investing.com India
Ovid Therapeutics Boosts Capital Through Warrant Exercises - TipRanks
Ovid Therapeutics receives $53.9 million from warrant exercises - Investing.com
Ovid Therapeutics sees $53.9M gross proceeds as Series A warrants mostly exercised - TradingView
Warrant exercises bring Ovid Therapeutics (NASDAQ: OVID) $53.9M cash - Stock Titan
H.C. Wainwright reiterates Ovid Therapeutics stock rating at buy - Investing.com
Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts - MarketBeat
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Announces Target Price $5.24 - 富途牛牛
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating - 富途牛牛
OVID.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
OVID Reiterated by Wedbush -- Price Target Maintained at $7.00 - GuruFocus
Leerink reiterates Ovid Therapeutics stock rating on KCC2 potential By Investing.com - Investing.com South Africa
Leerink reiterates Ovid Therapeutics stock rating on KCC2 potential - Investing.com
Ovid Therapeutics' (OVID) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS DisordersSlideshow - Seeking Alpha
Value Recap: What hedge funds are buying Ovid Therapeutics Inc2026 Analyst Calls & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Short Interest in Ovid Therapeutics (NASDAQ:OVID) Increases By 71.2% - MarketBeat
VIX Spike: Does Ovid Therapeutics Inc have declining or rising EPS2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
HC Wainwright Issues Positive Forecast for OVID Earnings - MarketBeat
Whale Trades: What are Ovid Therapeutics Incs growth levers2026 Gainers & Low Volatility Stock Recommendations - baoquankhu1.vn
OVID Should I Buy - Intellectia AI
H.C. Wainwright raises Ovid Therapeutics stock price target to $4 By Investing.com - Investing.com Australia
[Form 4] Ovid Therapeutics Inc. Insider Trading Activity - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) director granted RSUs in lieu of cash pay - Stock Titan
Director Kevin Fitzgerald awarded Ovid Therapeutics (OVID) RSU compensation - Stock Titan
Trade Recap: Why is Ovid Therapeutics Inc stock going up2026 Top Gainers & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Ovid Therapeutics Surge: Positive Phase 1 Data Ignites Market Confidence - timothysykes.com
Ovid Therapeutics (OVID): HC Wainwright & Co. Raises Price Targe - GuruFocus
H.C. Wainwright raises Ovid Therapeutics stock price target to $4 - Investing.com
Big Money Moves: Why is Ovid Therapeutics Inc stock going up - baoquankhu1.vn
Ovid Therapeutics Inc. (OVID) stock price, news, quote and history - Yahoo Finance UK
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 - The Manila Times
Ovid Therapeutics Shares Surge After Positive Phase 1 Results and Financing News - StocksToTrade
Earnings Report: Is Ovid Therapeutics Inc being accumulated by smart money2026 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Is Ovid Therapeutics (OVID) Stock Trending Up | Price at $2.31, Up 4.77%Open Stock Picks - Xã Thanh Hà
Ovid Therapeutics Inc (OVID) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Ovid Therapeutics Inc (OVID) 財務データ
収益
当期純利益
現金流量
EPS
1.77%
0.25%
大文字化:
|
ボリューム (24 時間):